Medtronic Reveals Regulatory Milestones for Software Used With Cardiac Ablation Platforms

10:41 AM EDT, 09/30/2026 (MT Newswires) -- Medtronic (MDT) said Wednesday it has received US Food and Drug Administration clearance and a CE Mark for its Affera Prism-2 Mapping Software. The medical technology manufacturer also obtained a CE Mark for its PulseSelect ProxBox Adapter software to expand its cardiac ablation product line, the company said. The Affera application generates three-dimensional maps of electrical activity in the heart to guide physicians during arrhythmia treatments, Medtronic said. The PulseSelect upgrade delivers real-time feedback to help doctors evaluate catheter proximity to targeted tissue before applying energy, the company added. Price: 86.53, Change: -0.56, Percent Change: -0.64